CME Information
This activity is jointly provided by Global Education Group (Global) and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC), in collaboration with BrightFocus Foundation.
Acknowledgement
This activity is supported by an educational grant from Eisai, Inc.
Credits Available
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
All other healthcare professionals completing this course will be issued a statement of participation.
Date of Release/Expiration
This activity was released on December 16, 2025, and is valid until December 16, 2026. Requests for credit must be made no later than December 16, 2026.
Target Audience
The educational design of this activity addresses the needs of neurologists, psychiatrists, and geriatricians.
Program Overview
With the approval of new anti-amyloid therapies, the treatment landscape for Alzheimer’s disease (AD) is entering an exciting new era. These advances bring fresh opportunities to enhance patient care, especially when paired with early diagnosis and biomarker-driven decision-making.
In this dynamic and informative program, two expert neurologists will examine the mechanisms of action, and efficacy and safety findings of approved targeted treatments. They’ll discuss strategies for engaging patients and caregivers in shared decision-making, improving access to new therapies, and monitoring for adverse events. The conversation will be grounded in the real-world patient experience, framed by a pre-recorded video vignette that brings the perspective of those living with early AD to the forefront.
Learning Objectives
After completing this activity, the participant should be better able to:
- Compare available anti-amyloid therapies for early Alzheimer’s disease by their mechanisms of action, pivotal trial outcomes, and administration considerations
- Evaluate initial real-world observations and guidance with anti-amyloid therapies
- Assess validated and emerging biomarkers and diagnostic tests to support an earlier and accurate diagnosis of Alzheimer’s disease and initiate timely therapeutic interventions
- Identify how to implement patient-centered treatment strategies using shared decision-making to align anti-amyloid therapy with individual clinical profiles
Faculty
David C. Weisman, MD
Director of the Clinical Trial Center
Abington Neurological Associates
Justin S. Moon, MD, MPH
Neurologist
Owner and Director
Denver Neurological Clinic
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC) Global is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Estimated Time to Complete
This activity should take approximately 60 minutes to complete.
Instructions to Receive Credit
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a score of 70% on the post-test.
Hardware/Software Requirements
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
Fee Information & Refund/Cancellation Policy
There is no fee for this educational activity.
Disclosures of Relevant Financial Relationships
Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
The planners and managers at Global Education Group and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC) have no relevant financial relationships to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and MedliveCME, LLC (previously known as PlatformQ Health Education, LLC) do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Contact Information
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or [email protected].
Technical Support:
For any technical issues or issues with your CME Certificate, please contact Medlive at 877-394-1306 or at [email protected].